Molecular targets and pathways involved in liver metastasis of colorectal cancer

Clinical and Experimental Metastasis

Volumn 32, Issue 6, 2015, Pages 623-635

  Weidle, Ulrich H ^a   Birzele, Fabian ^b   Krüger, Achim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Colorectal cancer; Liver metastasis; Metastasis models; Metastasis promoting genes; Metastatic cascade; Metastatic signalling

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CALGRANULIN A; CALVASCULIN; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; METASTASIS ASSOCIATED IN COLON CANCER 1; NERVE CELL ADHESION MOLECULE L1; NOTCH RECEPTOR; PRL3 PROTEIN; PROTEIN TYROSINE PHOSPHATASE; PROTEINASE; SCATTER FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TUMOR PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER CELL; CANCER CELL LINE; CELL INTERACTION; CELL MEMBRANE; COLORECTAL CANCER; ENZYME INHIBITION; FIBROBLAST; HUMAN; LIVER METASTASIS; NONHUMAN; PERICYTE; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL RATE; TUMOR GENE; ANIMAL; COLORECTAL TUMOR; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SECONDARY;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84937968894     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9732-3     Document Type: Review

References (138)

1. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170
2. Velculescu VE, Vogelstein B, Kinzler KW (2000) Analysing uncharted transcriptomes with SAGE. Trends Genet 16:423–425
3. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460
4. Hölzl D, Eckel R, Engel J (2009) Colorectal cancer metastasis. Frequency, prognosis and consequences. Chirurg 80:331–340
5. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenz R, Abbruzzese JL (2006) Metastatic patterns in adenocarcinoma. Cancer 106:1624–1633
6. Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nat Med 19:1450–1564
7. Deneve E, Rietdorf S, Ramos J et al (2013) Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 59:1384–1392
8. MacDonald IC, Groom AC, Chambers AF (2002) Cancer spread and micrometastasis development: quantitative approaches for in vivo models. BioEssays 24:885–893
9. Padget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571–573
10. Sceneay J, Smith MJ, Möller H (2013) The pre-metastatic niche: finding common ground. Cancer Metastasis Rev 32:449–464
11. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284
12. Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119:1429–1437
13. Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194:701–704
14. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98:10356–10361
15. Kirchner T, Brabletz T (2000) Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with human gastrulation. Am J Pathol 157:1113–1121
16. Placke T, Kopp HG, Salih HR (1996) The wolf in sheeps clothing: platelet derived “pseudo-self” impairs cancer cell “missing self” recognition by NK cells. Oncoimmunology 1:557–559
17. Bayon LG, Izquierdo MA, Sirovich I, van Rooijen N, Beelen RH, Meijer S (1996) Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology 23:1224–1231
18. Luo DZ, Vermijlen D, Ahisali B, Triantis V, Plakoutsi G, Braet F, Vanderkerken K, Wisse E (2000) On the biology of pit cells, the liver-specific NK cells. World J Gastroenterol 6:1–11
19. Wellner UF, Keck T, Brabletz T (2010) Liver metastases: pathogenesis and oncogenesis. Chirurg 81:551–556
20. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359:2814–2823
21. Paschos KA, Majeed AW, Bird NC (2014) Natural history of hepatic metastases from colorectal-pathological pathways with clinical significance. World J Gastroenterol 20:3719–3737
22. Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 77:1303–1308
23. Morikawa K, Walker SM, Jessup JM, Fidler IJ (1988) In vivo selection of highly metastatic cells from surgical specimens of different human primary colon carcinomas in nude mice. Cancer Res 48:1943–1948
24. Fidler IJ (1991) Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 10:229–243
25. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ (1988) Influence of organ environment on the growth, selection and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863–6871
26. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D (1994) Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13:209–243
27. Radinski R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1:19–31
28. Kitadai Y, Bucana CD, Ellis LM, Anzai H, Tahara E, Fidler IJ (1995) In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am J Pathol 147:1238–1247
29. Takahashi Y, Llis LM, Wilson MR, Bucana CD, Kitadai Y (1996) Progressive upregulation of metastasis-related genes in human colon cancer cells implanted into the cecum of nude mice. Oncol Res 8:163–169
30. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ (2006) Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 169:2054–2065
31. Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim JS, Langley RR, Fan D, Wang X, Do KA, Kim SJ, Fidler IJ (2008) Targeting EGFR, VEGFR, and PDGFR on colon cancer cells is required for therapy. Clin Exp Metastasis 25:477–489
32. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ (1997) Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15:3083–3090
33. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TH (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190
34. Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 390:91–97
35. Overall CM, Lopez-Otin C (2007) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–672
36. Krüger A (2009) Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biol Chem 390:91–97
37. Krüger A, Kates RE, Edwards DR (2009) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803:95–102
38. Han J, Gao B, Jin X, Li Z, Sun Y, Song B (2012) Small interfering RNA down-regulation of β-catenin inhibits invasion of colon cancer cells in vitro. Med Sci Monit 18:BR273–BR280
39. Damodharan U, Ganesan R, Radhakrishnan UC (2011) Expression of MMP2 and MMP9 gelatinases in human colon cancer cells. Appl Biochem Biotechnol 165:1245–1252
40. Krüger A, Soeltl R, Sopov I, Kopitz C, Artl M, Magdolen V, Harbeck N, Gänsbacher B, Schmitt M (2001) Hydroxamate-type matrix metalloprotease inhibitor batimastat promotes liver metastasis. Cancer Res 61:1272–1275
41. Clinchi B, Fransson A, Druvefors B, Hellsten A, Hakansson A, Gustavson B, Sjödahl R, Hakanson L (2007) Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma. Cancer 109:1742–1749
42. Gerg M, Kopitz C, Schaten S et al (2008) Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Mol Cancer Res 6:341–351
43. Arlt M, Kopitz C, Pennington C et al (2002) Increase in gelatinase-specificity of matrix metalloprotease inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res 62:5543–5550
44. Seubert B, Grünwald B, Kobuch J et al (2014) TIMP1 creates a pre-metastatic niche in the liver through SDF/CXCR4-dependent neutrophil recruitment in mice. Hepatology 61:238–248
45. Moller Sorensen N, Veigaard Sorensen I, Ornbierg Würtz S et al (2008) Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 43:774–786
46. Holten-Andersen MN, Stephens RW, Nielsen HJ et al (2000) High preoperative plasma tissue inhibitor of metalloproteinases-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6:4292–4299
47. Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9:285–293
48. Peinado H, Lavotshkin S, Lyden D (2011) The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21:139–146
49. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103
50. Liu Y, Yu X-F, Zou J, Luo Z-H (2015) Prognostic value of c-MET in colorectal cancer: a meta-analysis. World J Gastroenterol 21:3706–3710
51. Liu Y, Li Q, Zhu L (2012) Expression of hepatocyte growth factor and c-MET in colon cancer: correlation with clinicopathological features and overall survival. Tumori 98:105–112
52. Luraghi P, Schelter F, Krüger A, Boccaccio C (2012) The MET oncogene as a therapeutic target in cancer invasive growth. Front Pharmacol 3:164
53. Kopitz C, Gerg M, Bandapalli OR et al (2007) Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67:8615–8623
54. Murphy G (2011) Tissue inhibitors of metalloproteases. Genome Biol 12:233
55. Schelter F, Grandl M, Seubert B et al (2011) Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met signaling via inhibition of Adam-10. Clin Exp Metastasis 28:793–802
56. Schrötzlmair F, Kopitz C, Halbgewachs B (2010) Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase type plasminogen activator. J Cell Mol Med 14:2760–2770
57. Schelter F, Halbgewachs B, Bäumler P et al (2010) Tissue inhibitor of metalloproteinases-1 induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α. Clin Exp Metastasis 28:91–99
58. Schelter F, Gerg M, Halbgewachs B et al (2010) Identification of survival-independent metastasis enhancing role of hypoxia-inducible factor-1 alpha with a hypoxia-tolerant tumor cell line. J Biol Chem 285:26182–26189
59. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR (2006) Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25:3934–3942
60. Toricelli M, Melo FH, Peres GB, Siulva DC, Jasiulionis MG (2013) Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3 K signaling pathway independently of Akt phosphorylation. Mol Cancer 12:51
61. Puissegur MP, Mazure NM, Bertero P et al (2011) miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 18:465–478
62. Cui A, Seubert B, Stahl E et al (2014) Tissue inhibitor of metalloproteinases-1 induces a protumorigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene in press
63. Cui H, Grosso S, Schelter F, Mari B, Krueger A (2012) On the prometastatic stress response in cancer therapies: evidence for a positive cooperation between TIMP-1, HIF-1α and miR-210. Front Pharmacol 3:134
64. Mason SD, Joyce JA (2011) Proteolytic networks in cancer. Trends Cell Biol 21:228–237
65. Sorensen NM, Byström P, Christensen IJ et al (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving a combination of irinotecan, 5-fluoruracil, and folinic acid. Clin Cancer Res 13:4117–4122
66. Stein U, Walther W, Arlt F et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59–67
67. Isella C, Mellano A, Galimi F et al (2013) MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg 257:1089–1095
68. Stein U, Burock S, Herrmann P et al (2012) Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS ONE 7:e49249
69. Stein U, Dahlmann M, Walther W (2010) MACC1 – more then metastasis? Facts and predictions about a novel gene. J Mol Med 88:11–18
70. Arlt F, Stein U (2009) Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 41:2356–2359
71. Zhang Y, Wang Z, Chen M et al (2012) MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 11:23
72. Ostman A, Hellberg C, Böhmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6:307–320
73. Bessette DC, Qui D, Pallen C (2008) PRL PTPs: mediators and markers of cancer prognosis. Cancer Metastasis Rev 27:231–252
74. Lee SK, Han YM, Yun J et al (2012) Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells. Int J Cancer 131:E190–E203
75. Al-Aidaroos AQ, Yuen HD, Guo K (2013) Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest 123:3459–3471
76. Al-Aidaroos AQ, Zeng Q (2010) PRL3 phosphatase and cancer metastasis. J Cell Biochem 111:1087–1098
77. Saha S, Bardelli A, Buckhaults P et al (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294:1343–1346
78. Bardelli A, Saha S, Sager JA et al (2003) PRL-3 expression in metastatic cancers. Clin Cancer Res 9:5607–5615
79. Zeng Q, Dong JM, Guo K et al (2003) PRL-3 and PRL-1 promote cell migration, invasion and metastasis. Cancer Res 63:2716–2722
80. Jiang Y, Liu XQ, Rajput A et al (2011) Phosphatase PRL-3 is a direct regulatory target of TGFβ in colon cancer metastasis. Cancer Res 71:234–244
81. Guo K, Tang JP, Tan CP, Wang H, Zeng Q (2008) Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 7:750–757
82. Guo K, Tang JP, Al-Aidaroos AQ et al (2012) Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 3:158–171
83. Weidle UH, Eggle D, Klostermann S (2009) L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 29:4919–4931
84. Gavert S, Conacci-Sorell M, Gast D et al (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon tumors. J Cell Biol 168:633–642
85. Gerg M, Kopitz C, Schaten S et al (2008) Distinct functionality of tumor-cell derived gelatinases during formation of liver metastases. Mol Cancer Res 6:341–351
86. Weinspach D, Seubert B, Schaten S et al (2014) Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization and metastatic growth. Clin Exp Metastasis 31:87–100
87. Lim IT, Brown S, Mobashery S (2004) A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent. J Org Chem 69:3572–3573
88. Coutelle O, Nyakatura G, Tsudien S et al (1998) The neural cell adhesion molecule L1: genomic organisation and differential splicing is conserved between man and the pufferfish fugu. Gene 208:7–15
89. De Angelis E, Brummendorf T, Cheng L, Lemmon V, Kenwrick S (2001) Alternative use of a mini exon of the L1 gene affects L1 binding to neural ligands. J Biol Chem 276:32738–32742
90. Kamiguchi H, Long KE, Pendergast M, Schaefer AW, Rapoport I, Kirchhausen T, Lemmon V (1998) The neural cell adhesion molecule L1 interacts with the AP-2 adaptor and is endocytosed via its clathrin-mediated pathway. J Neurosc 18:5311–5321
91. Hauser S, Bickel L, Weinspach D et al (2011) Full-length L1CAM and not its ∆2∆27 splice variant promotes metastasis through induction of gelatinase expression. PLoS One 6:e18989
92. Gast D, Riedle S, Kiefel H et al (2008) The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Exp Cell Res 314:2411–2418
93. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Zeév A (2010) Nuclear factor-kappa B signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 123:2135–2143
94. Gast D, Riedle S, Issa Y et al (2008) The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 27:1281–1289
95. Arlt M, Novak-Hofer I, Gast D et al (2006) Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66:936–943
96. Wolterink S, Moldenhauer G, Fogel M et al (2010) Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 70:2504–2515
97. Schäfer H, Dieckmann C, Kornijenko O et al (2012) Combined treatment of L1CAM antibodies and cytotstatic drugs improve the therapeutic response to pancreatic and ovarian carcinoma. Cancer Lett 319:66–82
98. Kaifi JT, Reichelt U, Quaas A et al (2007) L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 20:1183–1190
99. Boo YJ, Park JM, Kim J et al (2007) L1 expression as a marker for poor diagnosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 14:1703–1711
100. Gavert N, Sheffer M, Raveh S et al (2007) Expression of L1-CAM and ADAM 10 in human colon cancer cells induces metastasis. Cancer Res 67:7703–7712
101. Gavert N, Conacci-Sorrell M, Gast D et al (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168:633–642
102. Gavert N, Ben-Shmuel A, Raveh S, Ben-Zeév A (2008) L1-CAM in cancerous tissues. Expert Opin Biol Ther 8:1749–1757
103. Trerotola M, Cantanelli P, Guerra E et al (2013) Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32:222–233
104. Wang J, Day R, Dong Y, Weintraub SJ, Michel L (2008) Identification of Trop-2 as an oncogene and an attractive target in colon cancers. Mol Cancer Ther 7:280–285
105. Cubas R, Zhang S, Li M, Chen C, Yao Q (2010) Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 9:253
106. Guerra E, Trerotola M, Aloisi AL et al (2013) The Trop-2 signaling network in cancer growth. Oncogene 32:1594–1600
107. Ohmachi T, Taneka Miori K, Inoue H, Yanaga K, Mori M (2006) Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 12:3057–3063
108. Fang YH, Lu ZH, Wang GQ et al (2007) Elevated expression of MMP7, TROP2, and Survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 24:875–884
109. Alberti S, Trerotola G, Vaca R et al (2007) TROP2 is a major determinant of growth and metastatic spreading of human cancer. J Clin Oncol 25(18S):10510
110. Donato R, Cannon BR, Sorci G et al (2013) Functions of S100 proteins. Curr Mol Med 1:24–57
111. Sack U, Walther W, Scuderio D et al (2011) S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 22:3344–3354
112. Cho YG, Kim CJ, Nam SW (2005) Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 11:4852–4856
113. Boye K, Nesland JM, Sandstad B, Maelandsmo GM, Flatmark K (2007) Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer 46:2919–2925
114. Dahlmann M, Sack U, Herrmann P et al (2012) Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation. Oncotarget 3:783–797
115. Stein U, Arlt F, Walther W et al (2006) The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 131:1486–1500
116. Ding Q, Chang CJ, Xie X et al (2011) APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest 121:4526–4536
117. Wang Q, Zhang YN, Lin GL et al (2012) S100P, a potential novel prognostic marker in colorectal cancer. Oncol Rep 28:303–310
118. Chandramouli A, Mercado-Pimentel ME, Hutchinson A et al (2010) The induction of S100P expression by the prostaglandin E2 PGE2/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol Ther 28:303–310
119. Dong L, Wang F, Yin X et al (2014) Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro. Mol Cell Biochem 389:257–264
120. Wong H, Schotz MC (2002) The lipase gene family. J Lipid Res 43:993–999
121. Nomura DK, Long JZ, Niessen S et al (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49–61
122. Notarnicola M, Messa C, Caruso MG (2012) A significant role of lipogenic enzymes in colorectal cancer. Anticancer Res 32:2585–2590
123. Silinsky J, Grimes C, Driscoll T et al (2013) CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis. J Surg Res 185:113–118
124. Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− colon cancer cells initiate tumors. J Clin Invest 118:2111–2120
125. Jaszczur M, Bertram JG, Pham P, Scharff MD, Goodman MF (2013) AID and Apobec3G haphazard deamination and mutational diversity. Cell Mol Life Sci 70:3089–3108
126. Huang J, Liang Z, Yang B, Tian H, Ma J, Zhang H (2007) Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members. J Biol Chem 282:33632–33640
127. Gallois-Montbrun S, Kramer B, Swanson CM et al (2007) Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol 81:2165–2178
128. Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumors: a little bit of everything but not all the time. Nat Rev Cancer 11:338–351
129. Sonoshita M, Aoki M, Fuwa H et al (2011) Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 19:125–137
130. Katz LH, Li Y, Chen J-S et al (2013) Targeting TGFβ signaling in cancer. Exp Opin Ther Targets 17:743–760
131. Pickup M, Novitsky S, Moses HL (2013) The role of TGFβ in the tumor microenvironment. Nat Rev Cancer 13:788–799
132. Zhang B, Halder SK, Kashikar ND et al (2010) Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 138:969–980
133. Halder SK, Rachakonda G, Deane NG, Datta PK (2008) Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer 99:957–965
134. Calon A, Espinet E, Palomo-Ponce S et al (2012) Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22:571–584
135. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460
136. Shibayama M, Maak M, Nitsche U et al (2011) Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic? Cancers 3:2858–2869
137. Taketo MM (2011) Reflections on the spread of metastasis to cancer prevention. Cancer Prev Res 4:324–328
138. Ye L-C, Liu T-S, Ren L et al (2013) Randomized controlled clinical trial of cetuximab plus chemotherapy for patients with KRAS unresectable colorectal liver-limited metastasis. J Clin Oncol 31:1931–1938